Biologics/Immunotherapy News

BOSTON — Patients with moderate to severe atopic dermatitis experienced relief with lebrikizumab for 52 weeks, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Physicians suspect the solvent used in the administration of pembrolizumab may have triggered recurrent angioedema for a patient with squamous cell carcinoma, according to a poster presented at the CHEST Annual Meeting.

BOSTON — Patients with hereditary angioedema who used deucrictibant for 12 weeks experienced improved symptom control, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Healio has compiled October’s most read news in asthma and allergy.

Caregivers of children with food allergy among minoritized racial and ethnic groups were less familiar with oral immunotherapy than caregivers of non-Hispanic white children with food allergy, according to a recent study.

BOSTON — Among caregivers of children with asthma, 54% did not “strongly agree” or “agree” that biologics are safe, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Patients with chronic spontaneous urticaria experienced significant improvements through 24 weeks with dupilumab, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Chronic spontaneous urticaria symptoms improved with 1 week of remibrutinib treatment, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Patients with hereditary angioedema saw significant reductions in attacks for 18 months after beginning berotralstat, according to two posters at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.